Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Eight RNAi-Related Patent Applications: Nov 29, 2007

Premium
Title: Inhibition of Hairless Protein mRNA
 
Number: 20070269395
 
Filed: Jan. 17, 2006
 
Inventor: Angela Christiano, Columbia University (Sirna Therapeutics)
 
According to its abstract, the patent application claims “methods for inhibition of hairless protein mRNA using RNA interference … in particular methods for hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of hairless protein mRNA and compositions including such constructs.”
 

 
Title: Multi-Targeting Interfering RNAs Having Two Active Strands and Methods for Their Design and Use
 
Number: 20070269815
 
Filed: Nov. 21, 2006
 
Lead Inventor: Laurent Pierre Rivory, Johnson & Johnson Research
 
“Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are used to modulate expression of the target sequences,” the patent application’s abstract states. “The multi-targeting interfering RNA molecules have two strands that target multiple target sites on one or more pre-selected RNA molecules. Such a multi-targeting interfering RNA approach provides a powerful tool for gene regulation.”
 

 
Title: Stabilized siRNAs as Transfection Controls and Silencing Reagents
 
Number: 20070269889
 
Filed: Feb. 4, 2005
 
Lead Inventor: Devin Leake, Dharmacon (Thermo Fisher Scientific)
 
The patent application, its abstract states, claims “RNA molecules, including siRNA molecules and related control, trackability and ex aequo agents with specific stability modifications. … These molecules are particularly advantageous as transfection control reagents.
 
“The molecules include first and second 5' terminal sense nucleotides with 2'-O-alkyl groups and a label on the first 5' terminal sense nucleotide, in conjunction with at least one additional 2'-O-alkyl pyrimidine-modified sense nucleotide, and either at least one 2' fluoro-modified pyrimidine antisense nucleotide and a phosphorylated first 5' terminal antisense nucleotide; or a first and second 5' terminal antisense nucleotide with 2'-O-alkyl modifications and at least one additional 2'-O-alkyl pyrimidine-modified antisense nucleotide,” the abstract adds.
 

 
Title: Formulations for Intracellular Delivery [of] dsRNA
 
Number: 20070269892
 
Filed: May 18, 2007
 
Lead Inventor: Roger Adami, Nastech Pharmaceutical
 
According to the patent application’s abstract, the invention is “a composition for delivery of [an] RNA molecule to a cell comprising: a double-stranded RNA molecule of about 15 to about 40 base pairs; and a cationic polymer peptide comprising at least two cysteine residues and at least one tryptophan residues with one or more repeats consisting of between about five to about 20 positively charged residues, a method for producing such composition, a method of using such composition to deliver dsRNA to a cell, and a method of using such composition to inhibit expression of a target gene.”
 

 
Title: RNA Interference-Mediated Inhibition of Severe Acute Respiratory Syndrome Gene Expression Using Short Interfering Nucleic Acid
 
Number: 20070270360
 
Filed: April 13, 2004 PCT Filed: April 13, 2004
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: Treatment of Eye Disorders Characterized by an Elevated Intraocular Pressure by siRNAs
 
Number: 20070270365
 
Filed: Aug. 23, 2005 PCT Filed: Aug. 23, 2005
 
Lead Inventor: Ana Jimenez, Sylentis
 
The patent application, its abstract states, claims “sequences and protocols for treatment of eye conditions by use of RNA interference. … Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis.”
 

 
Title: Double-Stranded Nucleic Acid Molecules Targeted to IL-4 Receptor Alpha
 
Number: 20070270366
 
Filed: Dec. 19, 2006
 
Lead Inventor: James Karras, Isis Pharmaceuticals
 
The patent application, its abstracts states, claims “compounds, compositions, and methods for modulating the expression of IL-4R alpha in a cell, tissue, or animal. Also provided are methods of target validation, [as well as] uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acid
 
Number: 20070270579
 
Filed: Sept. 23, 2005
 
Lead Inventor: Vasant Jadhav, Sirna Therapeutics (Merck)
 
“This invention relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid molecules,” the patent application’s abstract states. “In particular, the …. invention features small nucleic acid molecules … and methods used to modulate the expression of genes, such as expressed pseudogenes associated with the maintenance or development of diseases, disorders, traits, and conditions in a subject or organism. The invention also provides small nucleic acid molecules with reduced or attenuated immunostimulatory properties and methods for designing and synthesizing such small nucleic acid molecules having improved toxicologic properties while retaining RNAi activity.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.